Oleoylethanolamide treatment reduces neurobehavioral deficits and brain pathology in a mouse model of Gulf War Illness

• Published in: Scientific reports 2018-08, Vol.8 (1), p.12921-15, Article 12921
• Main Authors: Joshi, Utsav, Evans, James E., Joseph, Ross, Emmerich, Tanja, Saltiel, Nicole, Lungmus, Carlyn, Oberlin, Sarah, Langlois, Heather, Ojo, Joseph, Mouzon, Benoit, Paris, Daniel, Mullan, Michael, Jin, Chao, Klimas, Nancy, Sullivan, Kimberly, Crawford, Fiona, Abdullah, Laila
• Format: Article
• Language: English
• Subjects: 13/21; 13/51; 14/19; 14/63; 631/378/1689/1602; 631/378/371; 64/60; 82; 82/58; 82/80; Astrocytes; Chemokines; Cognitive ability; Dietary supplements; Fatigue; Fatty acids; Gulf War; Gulf War syndrome; Humanities and Social Sciences; Inflammation; Lipids; Microglia; Military personnel; multidisciplinary; NF-κB protein; Oleic acid; Oxidation; Peroxisomes; Persian Gulf War; Phosphorylation; Science; Science (multidisciplinary); Translation; War
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-31242-7

There are nearly 250,000 Gulf War (GW) veterans who suffer from Gulf War Illness (GWI), a multi-symptom condition that remains untreatable. The main objective was to determine if targeting peroxisomal function could be of therapeutic value in GWI. We performed a pilot study that showed accumulation of very long chain fatty acids (VLCFA), which are metabolized in peroxisomes, in plasma from veterans with GWI. We then examined if targeting peroxisomal β-oxidation with oleoylethanolamide (OEA) restores these lipids to the normal levels and mitigates neuroinflammation and neurobehavioral deficits in a well-established mouse model of GWI. In GWI mice, treatment with OEA corresponded with cognitive benefits and reduced fatigue and disinhibition-like behavior in GWI mice. Biochemical and molecular analysis of the brain tissue showed reduced astroglia and microglia staining, decreased levels of chemokines and cytokines, and decreased NFκB phosphorylation. Treatment with OEA reduced accumulation of peroxisome specific VLCFA in the brains of GWI mice. These studies further support the translational value of targeting peroxisomes. We expect that OEA may be a potential therapy for treating neurobehavioral symptoms and the underlying lipid dysfunction and neuroinflammation associated with GWI. Oleoylethanolamide is available as a dietary supplement, making it appealing for human translational studies.